Julia Briggs
Acute Care · Birch Run, MINPI 1962168591
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,305 of the $15,649 with a category attached, or 65.9%. 35 manufacturers reported payments, led by Johnson & Johnson at 40.6% of the total. 2025 is the largest year on record at $9,593, more than ten times the $446 reported in 2022. Among acute care clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 394 payments — averaging $39.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$6K
- AbbVie$3K
- QOL Medical, LLC$954
- Takeda Pharmaceuticals U.S.A., Inc.$870
- Gilead$710
- Sanofi$542
- plus $4K from 29 others
What the payments were for
- Speaking & faculty fees$4,30928%
- Travel & lodging$8716%
- Food & beverage$10,30566%
- Education$1641%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 61 | $6,351 |
| AbbVie | 98 | $2,678 |
| QOL Medical, LLC | 17 | $954 |
| Takeda Pharmaceuticals U.S.A., Inc. | 47 | $870 |
| Gilead | 25 | $710 |
| Sanofi | 17 | $542 |
| Pfizer | 22 | $456 |
| Intercept Pharmaceuticals, Inc. | 14 | $297 |
| Regeneron Healthcare Solutions, Inc. | 10 | $293 |
| Lilly USA, LLC | 8 | $183 |
| Ardelyx, Inc. | 8 | $177 |
| AstraZeneca | 3 | $159 |
| Intra-sana Laboratories | 5 | $156 |
| Regeneron | 1 | $145 |
| Novartis | 5 | $138 |
| Phathom Pharmaceuticals, Inc. | 2 | $133 |
| Boston Scientific | 1 | $130 |
| Janssen Scientific Affairs, LLC | 2 | $123 |
| Acadia Pharmaceuticals Inc | 1 | $123 |
| Ipsen Biopharmaceuticals, Inc | 6 | $110 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $96 |
| Organon | 4 | $86 |
| Celltrion USA Inc. | 4 | $84 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $80 |
| Melinta Therapeutics, LLC | 3 | $79 |
| Mallinckrodt Hospital Products Inc. | 3 | $79 |
| Aimmune Therapeutics, Inc. | 4 | $76 |
| Bristol Myers Squibb | 4 | $71 |
| Madrigal Pharmaceuticals | 2 | $55 |
| Kestra Medical Technology Services, Inc. | 1 | $47 |
| Evoke Pharma, Inc. | 3 | $43 |
| Merck | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 3 | $39 |
| Nestle Healthcare Nutrition Inc. | 1 | $25 |
| Braintree Laboratories, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,649 in reported general payments places this provider in the 95th percentile of 567 acute care providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 11 | $132,837 |
| LinzessLinaclotide | 31 | $32,487 |
| Mesalamine | 14 | $8,908 |
| Sucralfate | 18 | $1,727 |
| Omeprazole | 111 | $1,122 |
| Pantoprazole Sodium | 58 | $969 |
| Dicyclomine Hcl | 17 | $414 |
| Famotidine | 38 | $308 |
| Ondansetron OdtOndansetron | 20 | $217 |
| Amoxicillin | 12 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $2,678 | $32,48731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 567 acute care providers in Michigan.
Other acute care in Birch Run
- Janet WymanDetroit$103K
- Stephanie Mellon ReppenDetroit$57K
- Ashley WozniakLivonia$26K
- Candise LovePort Huron$14K
- Janette GuertinPort Huron$14K
- Gregory AliNovi$13K
- Andrew PalmerLansing$9K
- Angela BrennanDearborn Heights$7K
- Jennifer RutzenLansing$7K
- Holly WuestMonroe$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.